Select Page

Roche buying Promedior to develop drugs for fibrotic disease

Roche buying Promedior to develop drugs for fibrotic disease



The Swiss drug giant Roche (RHHBY) has agreed to pay $390 million upfront for a Lexington, Mass., biotech that has developed experimental drugs for fibrotic diseases, including a compound to treat a rare and fatal progressive lung disease.

Roche is buying Promedior to obtain its entire medicine portfolio — including its lead drug candidate, which showed encouraging results in a midstage clinical trial to treat idiopathic pulmonary fibrosis, a lung disorder.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED





Source link

About The Author

Leave a reply

Your email address will not be published. Required fields are marked *